aTyr Pharma Balance Sheet Health
Financial Health criteria checks 6/6
aTyr Pharma has a total shareholder equity of $84.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $113.3M and $29.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$84.50m |
Equity | US$84.28m |
Total liabilities | US$28.97m |
Total assets | US$113.25m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 471A's short term assets ($96.9M) exceed its short term liabilities ($16.0M).
Long Term Liabilities: 471A's short term assets ($96.9M) exceed its long term liabilities ($13.0M).
Debt to Equity History and Analysis
Debt Level: 471A is debt free.
Reducing Debt: 471A has no debt compared to 5 years ago when its debt to equity ratio was 48.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 471A has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 471A has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 8.9% each year.